Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors

NCT06157892 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT06157892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06157892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 20, 2024
Completion date
July 28, 2029
Enrollment
54 (actual)
Sites
135

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced gastric cancer, breast neoplasms, gastroesophageal junction adenocarcinoma, her2 low breast neoplasms, her2 positive breast neoplasms, metastatic breast cancer, metastatic gastric cancer, stomach neoplasms, triple negative breast neoplasms